Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1-Alpha Mutation Carriers

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Genetic Studies of Leptin Concentrations Implicate Leptin in the Regulation of Early Adiposity

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of endogenous GIP in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Danish comorbidity in liver transplant recipients study (DACOLT): a non-interventional prospective observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Sulfonylureas (SUs) provide an efficacious first-line treatment in patients with hepatocyte nuclear factor 1α (HNF1A) diabetes, but SUs have limitations due to risk of hypoglycemia. Treatment based on the incretin hor-mones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) is characterized by their glucose-dependent insulinotropic actions without risk of hypoglycemia. The effect of SUs together with GIP or GLP-1, respectively, on insulin and glucagon secretion in patients with HNF1A diabetes is currently unknown. To investigate this, 10 HNF1A mutation carriers and 10 control subjects without diabetes were recruited for a double-blinded, placebo-controlled, crossover study including 6 experimental days in a randomized order involving 2-h euglycemic-hyperglycemic clamps with coadministration of: 1) SU (glimepiride 1 mg) or placebo, combined with 2) infusions of GIP (1.5 pmol/kg/min), GLP-1(0.5pmol/kg/min),orsaline(NaCl).InHNF1A mutation carriers, we observed: 1) hypoinsulinemia,2) insulinotropic effects of both GIP and GLP-1, 3) additive to supra-additive effects on insulin secretion when combining SU+GIP and SU+GLP-1, respectively, and 4) increased fasting and arginine-induced glucagon levels compared with control subjects without diabe-tes. Our study suggests that a combination of SU and incretin-based treatment may be efficacious in patients with HNF1A diabetes via potentiation of glucose-stimulated insulin secretion.

Original languageEnglish
JournalDiabetes
Volume69
Issue number9
Pages (from-to)1989-2002
Number of pages14
ISSN0012-1797
DOIs
Publication statusPublished - Sep 2020

ID: 60285948